Borriello, Francesco (2020) Identification and characterization of STING as a robust adjuvant target for early life immunization. [Tesi di dottorato]

[img]
Anteprima
Testo
TesiFrancescoBorriello.pdf

Download (7MB) | Anteprima
[error in script] [error in script]
Tipologia del documento: Tesi di dottorato
Lingua: English
Titolo: Identification and characterization of STING as a robust adjuvant target for early life immunization
Autori:
AutoreEmail
Borriello, Francescofrancesco_borriello@hotmail.it
Data: 9 Marzo 2020
Numero di pagine: 45
Istituzione: Università degli Studi di Napoli Federico II
Dipartimento: Scienze Mediche Traslazionali
Dottorato: Medicina clinica e sperimentale
Ciclo di dottorato: 32
Coordinatore del Corso di dottorato:
nomeemail
Beguinot, Francescobeguino@unina.it
Tutor:
nomeemail
Marone, Gianni[non definito]
Data: 9 Marzo 2020
Numero di pagine: 45
Parole chiave: Vaccine; Influenza; STING
Settori scientifico-disciplinari del MIUR: Area 06 - Scienze mediche > MED/09 - Medicina interna
Depositato il: 26 Mar 2020 12:36
Ultima modifica: 10 Nov 2021 11:48
URI: http://www.fedoa.unina.it/id/eprint/13031

Abstract

Immunization is key to preventing infectious diseases, a leading cause of death early in life. However, due to age-specific immunity, vaccines often demonstrate reduced efficacy in newborns and young infants as compared to adults. Here, we combined in vitro and in vivo approaches to identify adjuvant candidates for early life immunization. We employed newborn and adult bone marrow-derived dendritic cells (BMDCs) to perform a screening of pattern recognition receptor agonists and found that the stimulator of interferon genes ligand 2'3'-cGAMP (hereafter cGAMP) induces a comparable expression of surface maturation markers in newborn and adult BMDCs. Then, we utilized the trivalent recombinant hemagglutinin (rHA) influenza vaccine, Flublok, as a model antigen to investigate the role of cGAMP in adult and early life immunization. cGAMP adjuvantation alone could increase rHA-specific antibody titers in adult but not newborn mice. Remarkably, as compared to alum or cGAMP alone, immunization with cGAMP formulated with alum (Alhydrogel) enhanced newborn rHA-specific IgG2a/c titers ~400-fold, an antibody subclass associated with the development of IFNγ-driven type 1 immunity in vivo and endowed with higher effector functions, by 42 days of life. Highlighting the amenability for successful vaccine formulation and delivery, we next confirmed that cGAMP adsorbs onto alum in vitro. Accordingly, immunization early in life with (cGAMP+alum) promoted IFNγ production by CD4+ T cells and increased the proportions and absolute numbers of CD4+ CXCR5+ PD-1+ T follicular helper and germinal center (GC) GL-7+ CD138+ B cells, suggesting an enhancement of the GC reaction. Adjuvantation effects were apparently specific for IgG2a/c isotype switching without effect on antibody affinity maturation, as there was no effect on rHA-specific IgG avidity. Overall, our studies suggest that cGAMP when formulated with alum may represent an effective adjuvantation system to foster humoral and cellular aspects of type 1 immunity for early life immunization.

Downloads

Downloads per month over past year

Actions (login required)

Modifica documento Modifica documento